SC
ICPT

Samlyn Capital’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Samlyn Capital’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-226,628
Closed -$18M – 151
2019
Q2 		$18M Buy
+226,628
New +$20.3M 0.38% 75

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Samlyn Capital's ICPT Position: Q3 2019 in Review

Samlyn Capital sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q3 2019, closing a stake of 226,628 shares — an estimated $18M sold.

Samlyn Capital first reported a position in ICPT in Q2 2019 and held it in 1 quarter. The position peaked at $18M in Q2 2019. 188 funds tracked by Wall St. Rank hold ICPT as of Q3 2019.

  • Samlyn Capital reported no remaining Intercept Pharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
  • Samlyn Capital sold 226,628 Intercept Pharmaceuticals, Inc. shares in Q3 2019, an estimated $18M.
  • Samlyn Capital first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2019 and held it in 1 quarter.
  • Samlyn Capital's Intercept Pharmaceuticals, Inc. position peaked at $18M in Q2 2019.
  • 188 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q3 2019.

Based on Samlyn Capital's 13F filing for Q3 2019, filed 14 Nov 2019.